Study reveals crucial details on skin-related side effects of cancer immune therapies
Investigators uncover 10 skin-related conditions linked to immune checkpoint inhibitors and identify which patients are more likely to develop them.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Dr. Kerry Reynolds is a physician at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School. She currently serves as the Director of the Severe Immunotherapy Complications Service, in addition to being the Clinical Director for the inpatient cancer services at Mass General Cancer Center.
To learn more about the Severe Immunotherapy Complications Service and research program - click here - https://www.massgeneral.org/cancer-center/treatments-and-services/severe-immunotherapy-complications/.
Dr. Reynolds specializes in the care of hospitalized patients. Under her leadership, the Massachusetts General Cancer Center’s inpatient program evaluates and treats over 4,000 patients each year and serves as a core training experience for Harvard Medical School students, residents, and fellows each year.
After completing her own residency, chief residency at Massachusetts General, and fellowship training in Oncology at Dana-Farber/Mass General Brigham Cancer Care, she joined the Harvard Medical School faculty in 2014, where she provides clinical care, supervises and educates trainees, participates in administrative affairs, and conducts research on severe toxicities associated with novel immunotherapy agents.
Her short-term academic and primary research focus is to create a clinical database and tissue collection infrastructure to capture the full national history of immune related adverse events (irAEs), and uncover predictors that will identify patients at highest risk for adverse events associated with immunotherapy, or those destined to be refractory. The overall goal is to characterize these severe clinical presentations, understand the blueprint of cells/molecules driving these clinical presentations, and ultimately develop new therapeutics to improve the treatment of this unique patient population.
Departments, Centers, & Programs:
Clinical Interests:
Treats:
MGH Cancer Center, Bartlett Hall
CHX-1 202
55 Fruit Street
Boston, MA 02114
Phone: 617-724-0549
Fax: 617-724-7799
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
We are in the midst of an exciting revolution in the treatment of cancer. By harnessing and enhancing the body’s immune system using novel therapies such as immune checkpoint inhibitors, we can reduce the amount of tumor burden in patients and, in a subset of patients and cancers, achieve long-lasting remission. However, these therapies are often limited by treatment-induced autoimmune adverse events. They affect nearly every organ system, ranging widely from minor rashes and fevers to severe gastrointestinal, pulmonary, or cardiac complications. Dr. Kerry Reynolds, along with Dr. Chloe Villani, and the Massachusetts General Hospital has taken a lead in this arena by altering our clinical practice model to provide expert multi-disciplinary care by creating the Severe Immunotherapy Complications Service. Importantly, this group is not just involved in the clinical care but they have banded together to set up infrastructure to empower specimen collection and facilitate translational research efforts, in order to understand the mechanisms driving immune-related adverse events (irAEs). Blood/tissue samples are systematically collected in an attempt to develop better therapies to treat autoimmune toxicities while maintaining anti-tumor immunity. The hope is that this will further our understanding of early mechanisms leading to autoimmune diseases and identify novel druggable targets with immunosuppressive potential. The Severe Immunotherapy Complications Service brings together expertise from a variety of clinical divisions and scientists across the institution to coordinate our care and tackle a critical problem facing many cancer patients today.
Selected Publications:
Molina GE, Zubiri L, et al, Reynolds KL. Temporal trends and outcomes among patients admitted for immune-related adverse events: A single-center retrospective cohort study from 2011-2018. Oncologist. 2021 Mar 3.
Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist. Jan 2020;25(1):6-14.
Reynolds KL, Sullivan RJ, Fintelmann FJ, Mansour MK, England J. Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia. N Engl J Med. Mar 2020;382(12):1150-1159
Reynolds KL, Guidon AC. Diagnosis and Management of Immune Checkpoint Inhibitor Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. Apr 2019
Additional publications can be found - https://www.massgeneral.org/cancer-center/treatments-and-services/severe-immunotherapy-complications/
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is the #1 Research Hospital in America and the only hospital to be recognized in all 16 specialties assessed by U.S. News & World Report.
Investigators uncover 10 skin-related conditions linked to immune checkpoint inhibitors and identify which patients are more likely to develop them.
Over the last decade, immunotherapies have increasingly offered hope to thousands of patients with cancer; however, this does not come without its adverse events (AEs), according to Kerry Reynolds, MD.
Mass General Cancer Center's Dr. Kerry Reynolds discusses the management of toxicities in an inpatient setting. This video was recorded on May 18, 2019 at the Annual Advances in Cancer Immunotherapy CME Course.
The challenge of immunotherapy side effects spurs clinicians and researchers at Mass General to find new and better ways to care for cancer patients.
Massachusetts General Hospital in Boston established its immunotherapy toxicity service care team in part because of the experience of David M., a patient treated there for metastatic melanoma that spread to the lung and brain.
The Severe Immunotherapy Complications Service at Mass General was created to address the urgent need to understand how and why toxicities occur, in order to develop new therapies that will allow patients to safely stay on their lifesaving immunotherapy regimens.